Addition of erlotinib to fluoropyrimidine-oxaliplatin-based chemotherapy with or without bevacizumab: Two sequential phase I trials

Author： Carlomagno Chiara   Daniele Gennaro   Bianco Roberto   Marciano Roberta   Damiano Vincenzo   Matano Elide   Nappi Lucia   Pepe Stefano   De Placido Sabino   Tortora Giampaolo  

Publisher： Spandidos Publications

ISSN： 1792-0981

Source： Experimental and Therapeutic Medicine, Vol.2, Iss.3, 2011-05, pp. : 449-455

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

CEA and CA19.9 as Early Predictors of Progression in Advanced/Metastatic Colorectal Cancer Patients Receiving Oxaliplatin-Based Chemotherapy and Bevacizumab

By Petrioli Roberto   Licchetta Antonella   Roviello Giandomenico   Pascucci Alessandra   Francini Edoardo   Bargagli Gianluca   Conca Raffaele   Miano Salvatora Tindara   Marzocca Giuseppe   Francini Guido    

Cancer Investigation, Vol. 30, Iss. 1, 2012-01 ,pp. : 65-71

Informa Healthcare

Access to resources Recommend Favorite

Phase I/II trial of capecitabine, oxaliplatin, and irinotecan in combination with bevacizumab in first line treatment of metastatic colorectal cancer

By  

Cancer Medicine, Vol. 2045-7634, Iss. 10, 2015-10 ,pp. : 1505-1513

John Wiley & Sons Inc

Access to resources Recommend Favorite

Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer

By  

Annals of Oncology, Vol. 24, Iss. 4, 2013-04 ,pp. : 1133-1133

Oxford University Press

Access to resources Recommend Favorite

Hyperfractionated Radiation Therapy plus Chemotherapy in Locally Advanced Cervical Cancer: Results of Two Phase I Dose- Escalation Gynecologic Oncology Group Trials

By Calkins A.R.   Harrison C.R.   Fowler W.C.   Gallion H.   Mangan C.E.   Husseinzadeh N.   Alvarez R.D.   Mychalczak B.   Podczaski E.  

Gynecologic Oncology, Vol. 75, Iss. 3, 1999-12 ,pp. : 349-355

Elsevier

Access to resources Recommend Favorite

Low expression of DLC1 is predictive of poor therapeutic efficiency of fluoropyrimidine and oxaliplatin as adjuvant chemotherapy in gastric cancer

By                

Molecular Medicine Reports, Vol. 12, Iss. 4, 2015-01 ,pp. : 5771-5779

Spandidos Publications

Access to resources Recommend Favorite